Scisparc Ltd
SPRC5.810USD
+0.110+1.93%
시장 운영 시간 （ET）시세는 15분 지연됩니다
290.26K시가총액
손실P/E TTM
자세한 내용은 Scisparc Ltd 회사
Scisparc Ltd, former Therapix Biosciences Ltd is a Israel-based pharmaceutical company commited into creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The company is engaged in drug development programs based on repurposing a cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), for the treatment of Obstructive Sleep Apnea (OSA), and the treatment of Pain; THX-130 for the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.
회사 정보
종목 코드 SPRC
회사 이름Scisparc Ltd
상장일Dec 22, 2021
CEOMr. Amitay Weiss
직원 수2
유형Ordinary Share
회계 연도 종료Dec 22
주소20 Raul Wallenberg Street, Tower A
도시TEL AVIV-YAFO
증권 거래소NASDAQ Capital Market Consolidated
국가Israel
우편 번호6971916
전화97236103100
웹사이트https://scisparc.com/
종목 코드 SPRC
상장일Dec 22, 2021
CEOMr. Amitay Weiss
회사 임원
이름
이름/직위
직위
주식 보유
변동
Mr. Itschak Shrem
Mr. Itschak Shrem
Chairman of the Board
Chairman of the Board
16.00
+128.57%
Mr. Amitay Weiss
Mr. Amitay Weiss
Chief Executive Officer, Director
Chief Executive Officer, Director
1.00
--
Prof. Ari Shamiss, M.D.
Prof. Ari Shamiss, M.D.
Independent Director
Independent Director
--
--
Mr. Alon Dayan
Mr. Alon Dayan
Independent Director
Independent Director
--
--
Dr. Adi Zuloff-Shani
Dr. Adi Zuloff-Shani
Chief Technology Officer
Chief Technology Officer
--
--
Mr. Amnon Shay
Mr. Amnon Shay
Independent Director
Independent Director
--
--
Mr. Moshe Revach
Mr. Moshe Revach
Director
Director
--
--
Mr. Lior Vider
Mr. Lior Vider
Independent Director
Independent Director
--
--
Ms. Liat Sidi
Ms. Liat Sidi
Director
Director
--
--
Mr. Oz Adler, CPA
Mr. Oz Adler, CPA
Chief Financial Officer
Chief Financial Officer
--
--
이름
이름/직위
직위
주식 보유
변동
Mr. Itschak Shrem
Mr. Itschak Shrem
Chairman of the Board
Chairman of the Board
16.00
+128.57%
Mr. Amitay Weiss
Mr. Amitay Weiss
Chief Executive Officer, Director
Chief Executive Officer, Director
1.00
--
Prof. Ari Shamiss, M.D.
Prof. Ari Shamiss, M.D.
Independent Director
Independent Director
--
--
Mr. Alon Dayan
Mr. Alon Dayan
Independent Director
Independent Director
--
--
Dr. Adi Zuloff-Shani
Dr. Adi Zuloff-Shani
Chief Technology Officer
Chief Technology Officer
--
--
Mr. Amnon Shay
Mr. Amnon Shay
Independent Director
Independent Director
--
--
수익 분석
데이터 없음
데이터 없음
사업별
지역별
데이터 없음
주식 보유 통계
마지막 업데이트: Wed, May 21
마지막 업데이트: Wed, May 21
주주
주주 유형
주주
주주
비율
Two Sigma Investments, LP
0.60%
Yorkville Advisors Global, LP.
0.49%
Other
98.91%
주주
주주
비율
Two Sigma Investments, LP
0.60%
Yorkville Advisors Global, LP.
0.49%
Other
98.91%
주주 유형
주주
비율
Hedge Fund
0.60%
Investment Advisor/Hedge Fund
0.49%
Other
98.91%
기관 주식 보유
마지막 업데이트: Tue, Jul 1
마지막 업데이트: Tue, Jul 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q2
20
5.88K
1.10%
-4.32K
2025Q1
22
123.94K
1.13%
-90.52K
2024Q4
22
186.52K
1.22%
-6.68K
2024Q3
20
179.36K
1.73%
+90.02K
2024Q2
22
138.03K
12.19%
+104.31K
2024Q1
20
67.89K
2.29%
+37.60K
2023Q4
19
11.96K
4.65%
-10.95K
2023Q3
23
5.71K
4.48%
-17.08K
2023Q2
22
12.21K
6.80%
-11.05K
2023Q1
20
14.22K
7.92%
-4.38K
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Two Sigma Investments, LP
3.21K
0.6%
+1.30K
+68.47%
Mar 31, 2025
Yorkville Advisors Global, LP.
2.63K
0.49%
+2.63K
--
Feb 27, 2024
Shrem (Itschak)
16.00
0%
+9.00
+128.57%
Apr 23, 2025
SBI Securities Co., Ltd.
14.00
0%
+11.00
+366.67%
Mar 31, 2025
BofA Global Research (US)
2.00
0%
-4.00
-66.67%
Mar 31, 2025
Rhumbline Advisers Ltd. Partnership
1.00
0%
-164.00
-99.39%
Mar 31, 2025
Weiss (Amitay)
1.00
0%
--
--
Apr 23, 2025
J.P. Morgan Securities LLC
--
0%
-22.00
-100.00%
Mar 31, 2025
Morgan Stanley & Co. LLC
--
0%
-18.00
-100.00%
Mar 31, 2025
Virtu Americas LLC
--
0%
-672.00
-100.00%
Dec 31, 2024
더 보기
관련 ETF
이름
비율
데이터 없음
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
Sep 20, 2023
Merger
26<1
Sep 20, 2023
Merger
26<1
Sep 20, 2023
Merger
26<1
Sep 20, 2023
Merger
26<1
날짜
유형
비율
Sep 20, 2023
Merger
26<1
Sep 20, 2023
Merger
26<1
Sep 20, 2023
Merger
26<1
Sep 20, 2023
Merger
26<1
